1 / 4

Impact of Pravastatin on Coronary Event Rates in Patients with Low LDL-C Levels

This study examines the effects of pravastatin on coronary event rates in patients enrolled in CARE and LIPID trials, specifically focusing on those with baseline LDL-C levels <125 mg/dL. The findings indicate significant differences in coronary event rates, highlighting a p-value of .004 in favor of pravastatin compared to placebo. The analysis also considers baseline characteristics including HDL-C, age, sex, hypertension, smoking, diabetes, BMI, and triglycerides. Results suggest potential implications for managing heart disease in patients with low LDL-C levels.

cana
Télécharger la présentation

Impact of Pravastatin on Coronary Event Rates in Patients with Low LDL-C Levels

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Prospective Pravastatin Pooling Project: Coronary Event Rates in CARE and LIPID Patients with Baseline LDL-C <125 mg/dL *p=.004; p=.005 for interaction Sacks FM et al. Circulation 2002;105:1424-1428.

  2. Prospective Pravastatin Pooling Project: Coronary Event Rates in CARE and LIPID Patients with Baseline LDL-C <125 mg/dL *p=.06 for RR in HDL-C groups and for interaction (HDL-C as continuous variable) †p=0.075; p=.09 for interaction Sacks FM et al. Circulation 2002;105:1424-1428.

  3. Prospective Pravastatin Pooling Project: Coronary Event Rates in CARE and LIPID Patients with Baseline LDL-C <125 mg/dL Coronary Event Rate (%) ** * Pravastatin *p=.004 **p (interaction) =.005 Placebo >60 <60 F M + — + — + — >27 <27 <40 >40 >150 <150 Age Sex HTN Smoking DM BMI HDL-C TG Sacks FM et al. Circulation 2002;105:1424-1428.

  4. 0 1 2 3 4 5 6 7 Cumulative Coronary Event Rates in Diabetic and Nondiabetic Patients with Baseline LDL-C <125 mg/dL Placebo Diabetic Pravastatin Nondiabetic Pravastatin Diabetic Placebo Nondiabetic Cumulative Risk of Coronary Event or Procedure (%) Years Follow-up Sacks FM et al. Circulation 2002;105:1424-1428.

More Related